l General Information |
Product Name | Lafutidine |
General description | Lafutidine, a newly developed histamine H(2)-receptor antagonist, inhibits gastric acid secretion. |
Synonym | FRG-8813; 2-(furan-2-ylmethylsulfinyl)-N-[(Z)-4-[4-(piperidin-1-ylmethyl)pyridin-2-yl]oxybut-2-enyl]acetamide |
Purity | ≥98.0%(HPLC) | CAS Number | 118288-08-7 |
Formula | C22H29N3O4S | Molecular Weight | 431.551 |
Suitability | BioReagent, suitable for cell culture, etc. |
l Physical and Chemical Information |
Appearance | white to beige powder |
Solubility(25°C) | DMSO | ≥50mg/mL |
Ethanol | ≥5mg/mL |
Water | Insoluble |
l Biological Information |
Biochem/Physiol
Actions | Lafutidine is a histamine H2-receptor antagonist that inhibits histamine-stimulated gastric acid secretion. Due to the resulting reduction in gastric volume and acidity, lafutidine can be used to treat ulcers and reflux. |
l Storage |
Storage temp. | -20°C |
l Precautions and Disclaimer |
This product is for R&D use only, not for
drug, household, or other uses. |
l References |
1. http://www.drugbank.ca 2. https://ncit.nci.nih.gov 3. https://www.ncbi.nlm.nih.gov |
